The Role of Early Molecular Response in the Management of Chronic Phase CML

Authors:

Abstract
Purpose of Review Although tyrosine kinase inhibitors (TKIs) spectacularly improve the disease burden and the overall survival of chronic myeloid leukemia patients, early identification of a subset of poor TKI responders has been recognized as a critical goal to prevent disease progression in these patients. We herein review the past and recent evidence on the impact of early response. Recent Findings In the recent years, the achievement of an early molecular response (EMR, defined as 3-month BCR-ABL1 transcript BCR-ABL1 transcript level (halving time or velocity of ratio reduction). Summary Standardization of halving time or velocity of ratio reduction will likely help establishing more stringent recommendation and modify current clinical practices.
Funding Information
  • King's College London

This publication has 39 references indexed in Scilit: